Table 3.
Change in HbA1c and weight from baseline patients initiating therapy with either exenatide QW or exenatide BID versus basal insulin: all patients
| 6 months | 12–24 months | |||||
|---|---|---|---|---|---|---|
| Exenatide QW | Basal insulin | p | Exenatide QW | Basal insulin | p | |
| HbA1c change from baseline | ||||||
| n | 244 | 3942 | 142 | 2024 | ||
| Mean (sd) absolute HbA1c change | − 1.29 (1.43) | − 1.46 (2.00) | − 1.24 (1.66) | − 1.47 (1.98) | ||
| Mean difference (95% CI) | 0.16 (− 0.09 to 0.42) | 0.210 | 0.24 (− 0.10 to 0.57) | 0.166 | ||
| Mean (sd) absolute HbA1c (mmol/mol) change | − 14.1 (15.6) | − 16.0 (21.9) | − 13.5 (18.1) | − 16.0 (21.6) | ||
| Mean difference (95% CI) | 1.75 (− 1.0 to 4.6) | 0.210 | 2.6 (− 1.1 to 6.2) | 0.166 | ||
| Weight change from baseline | ||||||
| n | 228 | 2960 | 126 | 1792 | ||
| Mean (sd) absolute change (kg) | − 3.76 (4.75) | 1.32 (5.25) | − 4.04 (6.4) | 2.24 (6.04) | < 0.001 | |
| Mean difference (95% CI) | − 5.08 (− 5.78 to − 4.38) | < 0.001 | − 6.37 (− 7.19 to − 5.54) | < 0.001 | ||
| 6 months | 12–24 months | |||||
|---|---|---|---|---|---|---|
| Exenatide BID | Basal insulin | p | Exenatide BID | Basal insulin | p | |
| HbA1c (%) change from baseline | ||||||
| n | 1646 | 3942 | 867 | 2024 | ||
| Mean (sd) absolute HbA1c (%) change | − 0.89 (1.62) | − 1.46 (2.00) | − 0.88 (1.75) | − 1.47 (1.98) | ||
| Mean difference (95% CI) | 0.57 (0.47–0.67) | < 0.001 | 0.59 (0.44–0.75) | < 0.001 | ||
| Mean (sd) absolute HbA1c (mmol/mol) change | − 9.7 (17.7) | − 16.0 (21.9) | − 9.6 (19.1) | − 16.0 (21.6) | ||
| Mean difference (95% CI) | 6.2 (5.1–7.3) | 6.5 (4.8–8.2) | 0.166 | |||
| Weight (kg) change from baseline | ||||||
| n | 1614 | 2960 | 841 | 1792 | ||
| Mean (sd) absolute change | − 4.09 (5.64) | 1.32 (5.25) | − 5.31 (6.55) | 2.24 (6.04) | ||
| Mean difference (95% CI) | − 5.41 (− 5.73 to − 5.08) | < 0.001 | − 7.55 (− 8.06 to − 7.04) | < 0.001 | ||